Cough, Nocturnal Cough, Upper Respiratory Infection
Conditions
Brief summary
Cough is a frequent symptom in children and infants and is one of the most common reasons parents visit a healthcare provider for their child. The US Food and Drug Administration has issued a warning that over-the-counter cough and cold medicines including antihistamines, decongestants, anti-tussives, and expectorants should not be administered to children younger than 2 years of age due not only to lack of proven efficacy, but also because of important safety concerns. A product that has been used in alternative medicine for cough is maple syrup. Although no studies have formally evaluated the use of maple syrup for nocturnal cough associated with URI, the demulcent effect of maple syrup may provide some relief from cough in children. A novel formulation of pasteurized maple cough syrup, when compared to placebo, should provide superior relief on nocturnal cough and the sleep difficulty associated with URI in children under 12 months and sleep difficulty of their parent/caregiver.
Interventions
DIETARY_SUPPLEMENTPasteurized maple syrup
DIETARY_SUPPLEMENTPlacebo
Sponsors
Advanced Clinical Research Services, LLC
Zarbee's Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
No minimum to 12 Months
Healthy volunteers
No
Inclusion criteria
1. Otherwise healthy male or female infant who is between 0 and 12 months of age. 2. Presents to clinic with a URI characterized by the presence of rhinorrhea and cough for 7 or fewer days' duration. 3. Patient is an appropriate candidate, in the judgment of the investigator, to participate in the study. 4. Parents/caregivers provide an answer of at least somewhat (3 points on a 7-point Likert scale) for a minimum of 2 of the 3 questions related to nocturnal cough frequency, effect on child's sleep, and effect on parental/caregiver sleep based on the previous night's symptoms (see Section 11.0). 5. Parent/legal authorized representative provides written informed consent for child to participate in study. 6. Parent/caregiver who is willing and able to comply with study requirements.
Exclusion criteria
1. Signs or symptoms of a more treatable disease (eg, asthma, pneumonia, laryngotrachebronchitis, sinusitis, allergic rhinitis). 2. Diagnosis of influenza, bronchiolitis or respiratory syncytial virus (RSV). 3. History of reactive airways disease, asthma, or chronic lung disease. 4. Use of any medication to treat cough within 6 hours of bedtime on the evening prior to or on the day of enrollment. (Use of analgesic medications such as acetaminophen or ibuprofen is not exclusionary.) 5. Presence of any significant disease including immunodeficiency, hepatic, renal, cardiovascular, or hematologic disease or any other health condition that, in the opinion of the investigator, would preclude participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in cough frequency between the first night and the end of the second night. | baseline and day 2 |
Countries
United States
Outcome results
None listed